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Summary We used RNAase protection and restriction fragment length polymorphism assays to detect
activating mutations of c-src in a spectrum of human tumours. No mutations were detected at codons 98, 381,
444, and 530. We conclude that mutational activation is not the mechanism of enhancement of pp60C.src-
specific kinase activity found in a number of human cancer types.
The src proto-oncogene (c-src) is the cellular homologue of
the transforming gene of the Rous sarcoma virus (RSV).
Both genes encode Mr 60,000 phosphoproteins (pp6O) which
are membrane bound and have tyrosine-specific protein ki-
nase activity (Collett & Erikson, 1978; Hunter & Sefton,
1980; Levinson et al., 1980). Comparison of the sequence of
v-src from a number of RSV strains, with the cellular c-src
gene, has shown that the transforming proteins contain a
number of common amino acid substitutions as well as dele-
tions of the terminal nineteen amino acids (summarised in
Hunter, 1987). Demonstration that a single point mutation is
capable of activating the oncogenic properties of pp60C-src has
been obtained from in vitro mutagenesis studies and analysis
of c-src transformation-competent mutants (Kmiecik & Shal-
loway, 1987; Piwnica-Worms et al., 1987; Cartwright et al.,
1987; Levy et al., 1986). There is considerable evidence that
TYR 527 is a negative regulator of kinase activity of pp6Oc-src
and its deletion in v-src contributes to the elevated kinase
activity of the viral protein. Substitution of TYR 527 with
amino acid residues which cannot be phosphorylated also
enhances the specific kinase activity of the molecule and
activates its transforming properties. Additional single point
mutations which activate the transforming ability of chicken
pp60csrc include amino acid substitutions in the kinase dom-
ain (THR 338, GLU 378, ILE 441) and mutations in the
amino terminus modulation domain, particularly at ARG 95.
All of the activating mutations of pp60csrc result in an in-
crease in the specific kinase activity of the molecule (Hunter,
1987).
pp60c-src tyrosyl kinase activity has been shown to be
elevated in a number of human cancers including colon
cancer, neuroblastoma, breast cancer and sarcomas (Jacobs
& Rubsamen, 1983; Bolen et al., 1985; Barnekow et al., 1987;
Bolen et al., 1987; Cartwright et al., 1989). For example,
from two-thirds to all of colon cancers tested have been
reported to have markedly elevated levels of pp60c-src kinase
activity (Bolen et al., 1987; Cartwright et al., 1989). The
increase in pp60csrc in these instances is associated with only
a modest increase in pp6Oc.src protein, suggesting that the
molecule is 'activated'. It is of importance to determine if the
augmentation of pp60c-src kinase activity is due to mutational
activation and we have addressed this directly by examining
the primary structure of the c-src gene in human primary
tumours. We have assayed for activating mutations at the
carboxy terminal phosphorylation regulatory site (TYR 530
in human pp60cSTc) as well as other regions in the kinase
domain and amino terminus capable of oncogenic activation
of the molecule. We have examined a spectrum of cancer
types, including colon cancers, which are associated with high
pp60csrc kinase activity.
We used two methods to score mutations at TYR 530 in a
total of 169 human tumours. A RNAase protection method
was used to assay 84 cancers. Radioisotopically-labelled anti-
sense RNA was generated from a SP-65 derived recombinant
plasmid we constructed, containing a 242 bp (BamHI-SmaI)
fragment of human c-src cDNA (Gibbs et al., 1985) encoding
amino acids 452-532 (Figure 1, probe D). To test the ability
of the RNAase protection assay to detect single base mismat-
ches at codon 530, we constructed a T to A mutation at the
second base of that codon using oligonucleotide-directed in
vitro mutagenesis (Kunkel, 1985) and cloned the mutated
fragment into a SP65-based vector. Using in vitro transcrip-
tion we generated sense strand RNA which was hybridised to
a radioisotopically-labelled anti-sense RNA probe. The hy-
brid was then subjected to the RNAase cleavage assay (des-
cribed in Figure 2). After hybridisation to the mutated RNA
and digestion with RNAase, the 317 nucleotide probe was
cleaved into the predicted fragments of 282 and 35 nucleo-
tides, indicating that the conditions used in this assay could
detect a single base mismatch at codon 530 (Figure 2a). The
size of the protected and cleaved probe fragments in this
experiment are larger than those obtained after hybridisation
with cellular RNA because the probe and the positive control
RNA contain common plasmid sequences not present in
cellular RNA.
We used this assay to detect c-src mutations in a variety of
tumours (43 colon cancers, 15 other solid tumours, 22 B-cell
lymphomas and four chronic myeloid leukaemias). In all
instances the assays yielded a full length protected probe (242
nucleotides) indicating that there were no mutations in the
samples tested. We analysed the products of the RNAase
reaction in long (43 cm) sequencing gels which could easily
detect a difference in mobility of six nucleotides. For exam-
ple, MspI digested PBR 322 DNA, used as a marker, yields a
doublet of 242 and 238 base pairs which are easily distin-
guishable. Representative RNAase protection assays from a
series of colon cancers, leukaemias and lymphomas are
shown in Figures 2b and 2c.
The RNAase protection assay also measures steady-state
mRNA levels, as can be seen from Figures 2b and 2c. A
marked variability in c-src specific mRNA levels was seen
among the different tumour specimens and will be addressed
in a subsequent report.
We then screened a number of human tumour DNA sam-
ples for c-src mutations using a restriction fragment length
polymorphism (RFLP) assay, taking advantage of a naturally
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Figure 1 Location of c-src probes used in I
assays. Probe A is a 173 bp Bgl-I-HincII
amino acids 57-114. Probe B is a 120 bp RsaI
amino acids 379-419. Probe C is a 100
encoding amino acids 419-452. Probe D is
SmaI fragment encoding amino acids 452-5.
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B C D occurring RsaI site which encompasses codon 530. Using
T primers which flank 3' and 5' to codon 530 we generated a
379 419 452 532 102 base pair polymerase chain reaction (PCR) amplification
, product. Upon cleavage with RsaI, fragments of 48 and 54
381 444 530 base pairs would be generated if codon 530 is unaltered. We
subjected 85 additional tumours to this assay (20 brain
516 cancers, 15 colon cancers, 27 other solid tumours, 19 lym-
phomas, four acute leukaemias). In all instances the PCR
RNAase protection product was completely digested (Figure 3). In order to test
fragment encoding the sensitivity of this assay we have performed reconstruction
Ifragment spanning assays in which varying amounts of mutated DNA were
bp AluI fragment mixed with normal cellular DNA. We found we could detect
a 242 bp BamHI- the mutation at a ratio of mutated DNA to normal DNA of
32. All DNA frag- 1:20 (unpublished results). These data are comparable to the ,for use in in vitro...
d in the c-src gene sensitivity of other mutation assays using RFLP analysis of
be detected in the PCR amplified products (Jiang et al., 1989).
We then utilised the RNAase protection assay to detect
mutations at and around amino acids 98, 381 and 444, using
the RNA probes described in Figure 1. Fifty-five tumours
(including 22 colon tumours, nine brain cancers, 11 other
solid tumours, 13 lymphomas and leukaemias) were analysed
,. Lt_ _1A_- _ A+Aw_ gAA_ A _ witn eacn probe ana in no instance was a mutation detected
(Figure 4).
In summary, we have been unable to detect activating
mutations of pp6oC-src at the carboxy terminal regulatory site
as well as a number of other relevant sites in the kinase
domain and amino terminus in a spectrum ofhuman cancers,
including those cell types in which the vast majority of
tumours have elevated pp6Oc-c kinase activity (e.g. colon
cancers). The RNAase protection assay we used employs
anti-sense RNA probes that will detect most mutations with
the exception of G:U mismatches (Borer et al., 1975).
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two of codon 530 would be detected. The RFLP assay will
detect all mutations at codon 530, provided cells containing
the mutation represent at least 5% ofthe tumour cell popula-
tion. Even with these constraints, it is likley that we would
have detected the majority of mutations at codon 530, and
the other sites, if they were present in the tumours tested.
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Figure 2 RNAase protection assay to detect codon 530 muta-
tions of c-src. Radioisotopically labelled anti-sense RNA was
generated from an SP65-derived recombinant plasmid we con-
structed containing a 242 bp (BamHI-SmaI) fragment of the
human c-src cDNA (probe D) (Figure 1). 1.0 x 105c.p.m. of
32P-labelled probe A RNA was hybridised to 301tg of whole cell
RNA in 30#LI of hybridisation solution containing 80% deionised
formamide, 0.4M NaCl, 1 mM EDTA, and 40 mM Pipes, pH 6.7.
The solution was heated to 85°C and then incubated at 56°C for
16 h. Following hybridisation, the reaction mixture was added to
300 Ll of digestion buffer (300 mm NaCl, 5 mM EDTA, 10mM
Tris-HCl, pH 7.5) containing 20 jAg ml-' of RNAase A. Follow-
ing incubation at 37'C for 1 h, samples were extracted with
phenol/chloroform and ethanol precipitated with 10iLg tRNA.
The precipitated RNA was resuspended in 10 jil of loading buffer
(97% deionised formamide, 0.1% NaDod So4, 10mM Tris-HCI,
pH 7.0) heated at 85°C for 3 min, and placed immediately at 4°C.
Samples were subjected to electrophoresis in an 8% acrylamide/
7 M urea vertical gel 43 cm in length. The gel was dried and
exposed to X-ray film at - 70C. a, Hybridisation of anti-sense
probe to RNA containing codon 530 mutation (lane 1) and
normal cellular RNA (lane 2). Following RNAase digestion the
probe that hybridised to mutated RNA is cleaved at the site of
the mismatch. b, RNAase assay of normal spleen (lane 1), B-cell
lymphomas (lanes 2-13), myeloid leukaemia (lanes 14-16), small
cell cancer of lung (lane 17). M-MspI digested PBR 322 DNA
marker; P - undigested probe. c, RNAase protection assay of a
series of colon carcinomas (lanes 1-10). Markers are Hae III
digested OX 174 and MspI digested PBR 322 DNA.
Figure 3 RFLP assay for RsaI site at codon 530. DNA was
amplified in a polymerase chain reaction using 30 thermal cycles
(95°C denaturation for 15s, 58°C annealing for 30s, and 72°C
extension for 1 min). The 5' end primer was: 5'TACCTGCAGG-
CCTTCCTG3' and the 3' end primer was: 5'GCCGAGAAGC-
CGGTC3'. The 102 bp product was analysed in an 8% polyacryl-
amide gel either uncut (u) or following digestion with RsaI (c).
Amplified DNA from 12 solid tumours is shown with complete
digestion of each sample with RsaI.
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Figure 4 RNAase protection assays for c-src mutations. Probe
A a, contains nucleotides 57-114, Probe B b, nucleotides
379-419, and Probe C c, nucleotides 419-452, as shown in
Figure 1. a, shows the assays of eight brain cancers; assays on
eight colon cancers are shown in b and c. No mutations were
detected.
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There are a number of alternative explanations for the
elevated pp60csrc kinase levels found in some cancers. First,
activating mutations other than those we tested for, may be
present in these cancers. For example, a mutation at amino
acid 338 is present in all strains of RSV. We have had
difficulty in establishing reproducible RNAase protection
assays for this region of the c-src gene. Nevertheless, we have
tested all of the other common mutation sites and have
obtained negative results. Second, a transformation-related
protein, similar to polyoma middle T antigen, may interact
with TYR 530 and prevent its phosphorylation (Courtneidge
& Smith, 1983). Activating endogenous cellular proteins,
similar to viral middle T antigen, have not yet been
identified. Third, and more likely, tumours with high pp6cC-src
activity may represent the clonal expansion of an
undifferentiated cell type with normally high pp60C-srC activity.
Colonic epithelial cells at a specific stage in development, e.g.
when they are actively dividing in an undifferentiated com-
partment, may normally possess high levels of pp6Oc-src
activity. It is of interest that colonic stem cells located at the
base of the colonic crypt have markedly elevated levels of
proteins phosphorylated on tyrosine residues as compared to
more mature epithelial cells at the top of the crypt (Burgess
et al., 1989). Additional evidence supporting a relationship
between pp6OC-src activity and the state of differentiation of
the colonic epithelium is demonstrated by experiments in
which butyrate-induced differentiation of human colon car-
cinoma cell lines was shown to down regulate pp60cs7c kinase
activity (Foss et al., 1989).
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